Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. develops clinical-stage cancer immunotherapies based on antibody engineering and target identification. Company news commonly covers its next-generation antibody therapeutics portfolio, including IPH4502, a Nectin-4 antibody-drug conjugate for solid tumors; lacutamab, an anti-KIR3DL2 antibody for cutaneous and peripheral T-cell lymphomas; monalizumab, an anti-NKG2A antibody developed with AstraZeneca for non-small cell lung cancer; and IPH5201, an anti-CD39 antibody studied in non-small cell lung cancer.
Updates also address collaborations with biopharmaceutical partners such as Sanofi and AstraZeneca, oncology conference presentations, business updates, annual meeting matters, share-count and voting-right disclosures, and annual reporting under French and U.S. public-company requirements.
Innate Pharma (NASDAQ: IPHA) will hold a conference call and webcast on Thursday, March 26, 2026 at 2:00 p.m. CET / 9:00 a.m. EDT following release of full-year 2025 financial results.
Senior management participating includes CEO Jonathan Dickinson and CFO Frédéric Lombard, among others. The live webcast and telephone registration links are available, and a replay will remain on the company website for 90 days.
Innate Pharma (Euronext: IPH, Nasdaq: IPHA) published its share and voting rights counts as of February 19, 2026. The company reports 93,743,243 ordinary shares outstanding, plus 6,140 Preferred Shares 2016 and 7,581 Preferred Shares 2017.
Total theoretical voting rights are 94,484,443 and total exercisable voting rights are 94,465,868, with the difference reflecting suspended or non-exercisable rights and AGAP-specific allocations.
Innate Pharma (Nasdaq: IPHA) will participate in the Leerink Partners Global Healthcare Conference in Miami from March 8–11, 2026. Company executives will take part in a fireside chat on March 9, 2026 at 3:40 PM ET / 8:40 PM CET.
According to the company, a live webcast and a replay of the presentation will be available via the Events page in the Investors section of Innate Pharma's website.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) disclosed its capital and voting structure as of December 31, 2025. The company reports 93,719,323 ordinary shares outstanding, plus 6,324 preferred shares 2016 and 7,581 preferred shares 2017. The total theoretical voting rights are 94,484,443 and the total exercisable voting rights are 94,465,868.
Explanatory notes clarify that theoretical voting rights include suspended rights and AGAP 2016 allotments, while exercisable voting rights exclude treasury shares with suspended votes, consistent with applicable AMF rules.
Innate Pharma (Euronext: IPH / Nasdaq: IPHA) disclosed its total shares and voting rights as of December 18, 2025. The company reported 92,197,823 ordinary shares outstanding. The total number of theoretical (gross) voting rights is 92,962,943 and the total number of exercisable (net) voting rights is 92,944,368. The gross voting rights figure includes voting rights attached to AGAP 2016 awards (130 for AGAP 2016-1 and 111 for AGAP 2016-2); no voting rights are attached to AGAP 2017. The exercisable voting rights exclude any shares with suspended voting rights, in line with AMF guidance.
Innate Pharma (Nasdaq: IPHA / Euronext: IPH) published its 2026 financial calendar with key publication and corporate dates. All scheduled reports will be released before market opens CET and corporate information will be available in the investors section of the company website.
- 26 Mar 2026 – Publication of 2025 financial statements
- 13 May 2026 – Publication of revenue and cash position for 1Q2026
- 21 May 2026 – Annual General Shareholders Meeting
- 17 Sep 2026 – Publication of half year financial statements
- 05 Nov 2026 – Publication of revenue and cash position for 3Q2026
Innate Pharma (Nasdaq:IPHA, Euronext:IPH) disclosed its capital and voting rights as of November 27, 2025. The company reports 92,196,523 ordinary shares outstanding plus 6,334 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total number of theoretical (gross) voting rights is 92,962,943 and the total number of exercisable (net) voting rights is 92,944,368.
The release cites Article L.233-8 II of the French Code de Commerce and Article 223-16 of the AMF General Regulation, and explains that theoretical voting rights include suspended rights and AGAP 2016 allocations, while exercisable voting rights exclude treasury-held shares with suspended voting rights.
Innate Pharma (Nasdaq: IPHA) will present at the Jefferies Global Healthcare Conference on November 17, 2025. Executive team members will hold one-on-one meetings and present a session from 2:30–2:55 PM GMT / 9:30–9:55 AM ET / 3:30–3:55 PM CET in London, UK.
A live webcast will be available via the Events page in the Investors section of Innate Pharma website for those who cannot attend in person.
Innate Pharma (NASDAQ:IPHA) reported Q3 2025 business and financial results on November 13, 2025. Key clinical milestones: FDA cleared the confirmatory Phase 3 protocol for lacutamab (TELLOMAK-3) enabling H1 2026 initiation and a potential accelerated approval path in Sézary syndrome; IPH4502 Phase 1 reached a pharmacologically active dose with enrollment continuing; monalizumab PACIFIC-9 data expected H2 2026. Financials: cash, equivalents and financial assets of €56.4 million as of Sept 30, 2025, with anticipated cash runway to end Q3-2026. Company reiterated ATM program of up to $75M and announced a planned redundancy plan to streamline operations.
Innate Pharma (Nasdaq: IPHA) announced that the U.S. FDA completed its review of the confirmatory Phase 3 protocol for lacutamab (TELLOMAK 3) with no further comments, clearing the study to proceed.
TELLOMAK 3 is an open-label, randomized Phase 3 in Sézary syndrome and Mycosis fungoides with two 1:1 cohorts versus romidepsin or mogamulizumab, using progression-free survival (PFS) by blinded central review as the primary endpoint. The company plans to initiate the trial in H1 2026 and notes the FDA provided initial feedback on a potential Accelerated Approval pathway for Sézary syndrome.